Safety of Kidney Transplantation Using Anti-HBc–Positive Donors

Abstract

BackgroundProspective studies evaluating the risk of hepatitis B virus (HBV) transmission in transplants of kidneys from hepatitis B core antibody (anti-HBc)–positive/hepatitis B surface antibody (anti-HBs)–negative donors are still lacking. The objective of this study was to assess the safety of kidney transplantation with the use of anti-HBc–positive donors. MethodsThis prospective case series study included 50 kidney transplant recipients from anti-HBc–positive donors with or without anti-HBs positivity. Recipients were required to test positive for anti-HBs (titers >10 mUI/mL), regardless of anti-HBc status, and negative for hepatitis B surface antigen (HBsAg). Recipient and donor data were retrieved from medical records, databases, and organ procurement organization sheets. Liver function tests were performed at progressively increasing post-transplantation intervals. Complete serologic tests for HBV were performed before transplantation, 3 and 6 months after transplantation, and annually thereafter. ResultsSix months after transplantation, all recipients were negative for HBsAg, HBeAg, anti-HBe, and anti-HBcIgM. No seroconversion was observed among the 20 patients who received kidneys from anti-HBc–positive/anti-HBs–negative donors. No patient showed elevated liver enzymes during follow-up. ConclusionsKidney transplantation using organs from anti-HBcIgG–positive donors (even when they are concurrently anti-HBs negative) in anti-HBs–positive recipients is a safe procedure and may be considered as a way to expand the donor pool.